Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Here are some of the biggest premarket US stock movers today: Goldman Sachs (NYSE: GS) stock rose 2.2% after the investment bank’s profit more than doubled in the fourth quarter, driven by strong ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Wells Fargo said fourth-quarter net interest income, a key metric for banks, fell 7% to $11.8 billion in the quarter from $12.8 billion for the same period last year. The bank said net interest income ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

Harbor Capital Advisors Inc. boosted its position in Oxford Industries, Inc. (NYSE:OXM – Free Report) by 14.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 5,853 shares of ...